Cipla Yurpeak (Tirzepatide)

Cipla Limited has launched Yurpeak (tirzepatide), a once-weekly injectable therapy for obesity and type 2 diabetes under its marketing and distribution agreement with Eli Lilly and Company (India).

The medication is designed for the treatment of Type-2 diabetes, a condition that continues to affect millions of people across the country.

Yurpeak available in six strengths available on prescription in the KwikPen device format: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg

As per the company, the launch of Cipla Yurpeak in India will help expand access to Tirzepatide so that more patients can benefit from this innovative therapy.

Key Highlights of the Agreement

Under this strategic partnership:

Lilly will manufacture and supply Yurpeak to Cipla.
Cipla will be responsible for the marketing and distribution of Yurpeak (tirzepatide), in India.
The pricing of Yurpeak (tirzepatide) will remain same to Eli Lilly’s existing brand Mounjaro, which is already available in India.

A Major Step for Diabetes Care in India

India has one of the highest populations of diabetes patients in the world, particularly Type-2 diabetes. The introduction of Yurpeak (tirzepatide) is expected to provide a valuable new treatment option.

Lilly’s Mounjaro

Eli Lilly’s Mounjaro, introduced in India in March 2025, has already received a strong response from both doctors and patients. Mounjaro rapidly became India’s top-selling medicine brand after its launch, posting Rs 100 crore in sales in October. Yurpeak (tirzepatide) is anticipated to extend the benefits of this category further.

Why This Partnership Strengthens Cipla’s Position

Cipla has one of the most extensive pharmaceutical distribution networks in India, ranked among the top two in the country. Eli Lilly benefits from Cipla’s strong distribution capabilities.

This gives Yurpeak (tirzepatide) an immediate advantage in terms of nationwide reach.
Cipla adds a high-demand, advanced diabetes therapy to its product portfolio, enhancing its position in the chronic care segment.

Possibility of Future Technology Transfer

Sources also indicate that:

There is potential for molecule technology transfer in the future.
If this materializes, Cipla may eventually manufacture Yurpeak (tirzepatide) locally, improving availability and potentially reducing costs over time.